Clinical Trials

  • IMMU-132 (Sacituzumab Govitecan)

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease. For more information on this clinical trial, which will soon be open for patient enrollment, please visit clinicaltrials.gov.

You can also send us an email.